DGAP-News: SYGNIS AG

PRESS RELEASE
15 March 2018
 

SYGNIS announces completion of Sales and Marketing team restructuring to support continued strong revenue growth

- Growth in team to over 30 staff over the past year

- Reorganisation of team to focus on separate revenue streams from product sales and partnering arrangements

- Sales and marketing focussed on supporting continued strong growth with Sygnis expecting to report sales of EUR 7.8 million (unaudited) for 2017 including like for like organic growth of 24%

Heidelberg, Germany and Cambridge, UK, 15 March 2018 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announced the restructuring of its sales and marketing team to drive continued strong revenue growth. A direct sales and distribution team focused on product sales has been formed while a business development team will focus on partnering and service opportunities. Both teams will be supported by marketing, responsible for maintaining the recently launched integrated Expedeon branded product website to drive strong lead and sales opportunity generation, as well as wider group marketing activities.

Acquisitions continue to make a major contribution to the year on year revenue growth from EUR 1.8 million in 2016 to EUR 7.8 million (unaudited) in 2017. Alongside this, our organic growth, a cornerstone of our 'grow, buy, build strategy', continued apace with year on year like for like growth of 24%, underpinned by our strong sales and marketing team.

These changes in the team follow significant expansion in the past year to well over 30 employees. The reorganisation will continue to support future strong revenue growth with our team focusing on delivering outstanding organic growth across our product and service portfolio.

Dr. Heikki Lanckriet, CEO and CSO of Sygnis AG commented: "We continue to focus on our 'grow, buy, build strategy' which has driven exciting revenue growth underpinned by a strong sales and marketing function. These changes were necessary to ensure we exploit the many commercial opportunities arising across our portfolio of products and technologies and which is supported by our very strong sales and marketing team. These building blocks have delivered year on year revenue growth including our benchmark organic growth."

For further information, please contact:

SYGNIS AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG (Investor Relations and International Media Relations)
Dr. Claudia Gutjahr-Löser
Managing Director
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

Zyme Communications (Trade and UK Media Relations)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About SYGNIS AG: www.sygnis.com
SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group's cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS' products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon brand. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###